{"nctId":"NCT00171340","briefTitle":"Zoledronic Acid in the Prevention of Cancer Treatment Related Bone Loss in Postmenopausal Women Receiving Letrozole for Breast Cancer.","startDateStruct":{"date":"2003-05"},"conditions":["Bone Loss","Breast Cancer"],"count":1065,"armGroups":[{"label":"Upfront Zoledronic Acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid","Drug: Letrozole"]},{"label":"Delayed Zoledronic Acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid","Drug: Letrozole"]}],"interventions":[{"name":"Zoledronic acid","otherNames":["ZOL446","Zometa®"]},{"name":"Letrozole","otherNames":["Femara®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Stage I-IIIa breast cancer\n* Postmenopausal or recently postmenopausal\n* Recent surgery for breast cancer\n* Estrogen Receptor positive and/or progesterone receptor positive hormone receptor status\n* No prior treatment with letrozole\n\nOther protocol-defined inclusion criteria may apply.\n\nExclusion Criteria:\n\n* Metastatic disease\n* Invasive bilateral disease\n* Clinical or radiological evidence of existing fracture in spine or hip\n* Prior treatment with IV bisphosphonates in the past 12 months\n* Current treatment with oral bisphosphonates ( must be discontinued within 3 weeks of baseline evaluation)\n* Use of Tibolone within 6 months\n* Prior use of parathyroid hormone for more than 1 week\n* Previous or concomitant malignancy\n* Abnormal renal function\n* History of disease effecting bone metabolism\n\nOther protocol-defined exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 12 Months of Therapy.","description":"Bone Mineral Density (g/cm\\^2) of the Lumbar Spine (L2-L4) as measured by energy x-ray absorptiometry (DXA).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.208","spread":"3.4194"},{"groupId":"OG001","value":"-3.617","spread":"4.2151"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Bone Mineral Density (BMD) of the Lumbar Spine (L2-L4) at 2, 3, 4 and 5 Years of Therapy.","description":"Bone Mineral Density (g/cm\\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.463","spread":"4.2691"},{"groupId":"OG001","value":"-4.601","spread":"5.5273"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.730","spread":"4.884"},{"groupId":"OG001","value":"-4.871","spread":"6.271"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.782","spread":"5.7300"},{"groupId":"OG001","value":"-5.154","spread":"7.1079"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.308","spread":"6.0242"},{"groupId":"OG001","value":"-5.414","spread":"7.6185"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Bone Mineral Density (BMD)of the Lumbar Spine (L1-L4) Over 5 Years of Therapy.","description":"Bone Mineral Density (g/cm\\^2) of the Lumbar Spine (L1-L4)as measured by dual energy x-ray absorptiometry (DXA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.128","spread":"3.2106"},{"groupId":"OG001","value":"-3603","spread":"4.1808"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.300","spread":"4.0700"},{"groupId":"OG001","value":"-4.521","spread":"5.2624"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.521","spread":"4.5936"},{"groupId":"OG001","value":"-4.869","spread":"6.0310"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.529","spread":"5.5410"},{"groupId":"OG001","value":"-5.148","spread":"6.8803"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.898","spread":"5.7995"},{"groupId":"OG001","value":"-5.427","spread":"7.4818"}]}]}]},{"type":"SECONDARY","title":"Percentage Change in Bone Mineral Density (BMD) of the Total Hip at 12 Months, 2 Years, 3 Years, 4 Years and 5 Years After Therapy.","description":"Bone Mineral Density (g/cm\\^2) of the Lumbar Spine (L2-L4) as measured by dual energy x-ray absorptiometry (DXA)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.222","spread":"2.3257"},{"groupId":"OG001","value":"-2.239","spread":"3.3614"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.649","spread":"2.7333"},{"groupId":"OG001","value":"-2.990","spread":"4.4318"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.754","spread":"3.1375"},{"groupId":"OG001","value":"-3.302","spread":"4.8942"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.716","spread":"3.5228"},{"groupId":"OG001","value":"-3.922","spread":"5.6505"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.615","spread":"3.7490"},{"groupId":"OG001","value":"-4.162","spread":"6.0270"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Clinical Fractures at 3 Years of Therapy Which Were Not Present at Baseline","description":"At 3 years of therapy the percentage of participants with fractures as detected by X-ray and/ or bone scan.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"1.5","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":133,"n":525},"commonTop":["Arthralgia","Hot flush","Fatigue","Bone pain","Back pain"]}}}